Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals, Inc. (AVIR)
:AVIR
AVIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.46 - $4.15
Previous CloseN/A
Volume180.19K
Average Volume (3M)386.41K
Market Cap
$289.66M
Enterprise Value-$76.98M
Total Cash (Recent Filing)$379.71M
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 06, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding79,357,550
10 Day Avg. Volume395,296
30 Day Avg. Volume386,411
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.27
Enterprise Value/Revenue-185.04
Enterprise Value/Gross Profit740.16
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$6.00Price Target Upside66.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentClinical development of their combination regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus is advancing across Ph3 trials.
Financial PositionStrong financial position with $425.4M in cash, extending runway into 2028.
Market OutlookGiven the negative enterprise value, the risk/reward symmetry is skewed to the upside, leading to a reiteration of the Outperform rating on Atea shares.
Bears Say
Earnings ReportAtea reported a net loss of $37.2 million, or a loss of $0.44 per share.
Financial PerformanceAtea reported a net loss of $33.5 million, or a loss of $0.40 per share.
Workforce ReductionA workforce reduction by 25% is planned during the first quarter, which could lead to roughly $15 million in cost savings through 2027.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals, Inc.’s price range in the past 12 months?
Atea Pharmaceuticals, Inc. lowest stock price was $2.46 and its highest was $4.14 in the past 12 months.
What is Atea Pharmaceuticals, Inc.’s market cap?
Atea Pharmaceuticals, Inc.’s market cap is $289.66M.
When is Atea Pharmaceuticals, Inc.’s upcoming earnings report date?
Atea Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
How were Atea Pharmaceuticals, Inc.’s earnings last quarter?
Atea Pharmaceuticals, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.025.
Is Atea Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Atea Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Atea Pharmaceuticals, Inc. pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
What is Atea Pharmaceuticals, Inc.’s EPS estimate?
Atea Pharmaceuticals, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Atea Pharmaceuticals, Inc. have?
Atea Pharmaceuticals, Inc. has 79,357,550 shares outstanding.
What happened to Atea Pharmaceuticals, Inc.’s price movement after its last earnings report?
Atea Pharmaceuticals, Inc. reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -2.312%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AVIR
Atea Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (66.67% Upside)
$6.00 (66.67% Upside)
Hedge Fund Trend
Increased
By 8.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.25%
12-Months-Change
Fundamentals
Return on Equity
-32.38%
Trailing 12-Months
Asset Growth
-23.27%
Trailing 12-Months
Company Description
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call emphasized significant progress in clinical trials, a strong financial position, and positive market reception for their HCV program. However, challenges such as slower regulatory approvals outside North America and decreased interest income were noted. Despite these challenges, the overall sentiment is optimistic with a focus on future growth and market disruption.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$6.00
▲(66.67% Upside)
Technical Analysis
Astria Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Humacyte
―
Candel Therapeutics
―
Ownership Overview
10.25% Insiders
14.42% Mutual Funds
23.00% Other Institutional Investors
41.11% Public Companies and
Individual Investors